Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07039942

French Prospective Multicentric Study in Real World

The purpose of this postmarket clinical investigation is to evaluate the levels of glycemic control, quality of life, and satisfaction, as well as the patient experience, and acute diabetes complication rates provided by the Omnipod 5 Automated Insulin Delivery System (referred to as the Omnipod 5 System) in a real-world setting.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Diabetes Autoimmune Diseases Diabetes Mellitus Diabetes Mellitus, Type 1 Endocrine System Diseases Glucose Metabolism Disorders Immune System Diseases Metabolic Diseases Nutritional and Metabolic Diseases Type 1 Diabetes

Age range

2 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Angers, Angers, France

Loading trial locations.

About this study

Twelve-month, real-world, non-interventional, prospective follow-up of adult and pediatric patients aged more than 2 years old, prescribed one of the Dexcom (Dexcom G6 or G7) configurations commercially available of the Omnipod 5 Automated Insulin Delivery System in France.

OPTIMAL-A study (Omnipod 5 - A French Prospective Multicentric Study in Real World), aims to provide the requisite real-world data on the glycemic control, quality of life, safety, and device usage profiles of users of the Omnipod 5 System during the 12 months after starting using Omnipod 5 in automated mode.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with T1D aged ≥ 2 years.
  • Patient prescribed a commercially available configuration of the Omnipod 5 System using a Dexcom sensor (Dexcom G6 or Dexcom G7).
  • Patient has never used the Omnipod 5 System prior to inclusion.
  • Patient has not objected to the use of their personal data for this study.
  • Patient or legal guardian has an email address and mobile phone number.
  • Patient (and legal guardians if the patient is a minor) is able to understand study information and Non-Opposition form.
  • Patient (and legal guardians if the patient is a minor) is able to understand and complete questionnaires in French.
  • Patient is covered by the local social security system.

Exclusion criteria

  • Patient is currently pregnant
  • Patient presents an allergy to the materials of the Omnipod 5 System (patch, cannula, CGM).
  • Patient is unable to be followed by the same investigation site for the duration of the study or is unwilling or unable to maintain contact with the healthcare professional.
  • Patient is already participating in a clinical trial or in another study precluding their participation in other studies.
  • Patient or legal guardian (for minors) is not able to understand and complete electronic questionnaires.
  • Adult under guardianship, curatorship or tutorship.
  • Adult otherwise deprived of liberty.

Treatment and study plan

OmniPod 5

Device

The Omnipod 5 Automated Insulin Delivery System (Omnipod 5 System) is a tubeless insulin pump with a mono-hormonal insulin delivery system designed to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in people aged 2 years and older who require insulin.

The Omnipod 5 System is intended to function as an automated insulin delivery system when used with compatible Continuous Glucose Monitoring (CGM) systems.

Primary outcomes

  1. Change in the percentage of time in the 70 - 180 mg/dL range (TIR)

    Time frame: 12 months following first initiation of automated mode

    Assess the effectiveness of the Omnipod 5 system in terms of glycemic control

Secondary outcomes

  1. Percentage of time in the 70 - 180 mg/dL range (TIR)

    Time frame: Up to 12-months following first initiation of automated mode

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

  2. Percentage of time in the 70 - 140 mg/dL range (TIR Tight)

    Time frame: Up to 12-months following first initiation of automated mode

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

  3. Percentage of time below 54 mg/dL (TBR Very Low)

    Time frame: Up to 12-months following first initiation of automated mode

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

  4. Percentage of time below 70 mg/dL (TBR Low)

    Time frame: Up to 12-months following first initiation of automated mode

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

  5. Percentage of time above 180 mg/dL (TAR High)

    Time frame: Up to 12-months following first initiation of automated mode

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

  6. Percentage of time above 250 mg/dL (TAR Very High)

    Time frame: Up to 12-months following first initiation of automated mode

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

  7. Glucose Management Indicator (GMI)

    Time frame: Up to 12-months following first initiation of automated mode

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

  8. Glycemic Risk Index (GRI)

    Time frame: Up to 12-months following first initiation of automated mode

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

  9. Coefficient of variation (CV)

    Time frame: Up to 12-months following first initiation of automated mode

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

  10. Mean glucose

    Time frame: Up to 12-months following first initiation of automated mode

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

  11. Laboratory HbA1c levels (if available)

    Time frame: Up to 12-months following first initiation of automated mode

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

  12. Percentage of patients with ≥ 70% TIR

    Time frame: Up to 12-months following first initiation of automated mode

    Assess the achievement of CGM-based consensus targets

  13. Percentage of patients with < 4% TBR Low

    Time frame: Up to 12-months following first initiation of automated mode

    Assess the achievement of CGM-based consensus targets

  14. Percentage of patients with < 1% TBR Very Low

    Time frame: Up to 12-months following first initiation of automated mode

    Assess the achievement of CGM-based consensus targets

  15. Percentage of patients with GMI ≤ 7%

    Time frame: Up to 12-months following first initiation of automated mode

    Assess the achievement of CGM-based consensus targets

  16. Percentage of patients with CV ≤ 36%

    Time frame: Up to 12-months following first initiation of automated mode

    Assess the achievement of CGM-based consensus targets

  17. Percentage of patients achieving combinations of previous CGM-based consensus targets

    Time frame: Up to 12-months following first initiation of automated mode

    Assess the achievement of CGM-based consensus targets

  18. EuroQoL 5-dimension 5-level questionnaire

    Time frame: At inclusion and 6 and 12 months following first initiation of automated mode

    Assess patients' general QoL

  19. Patients aged ≥ 18 years: Diabetes Quality of Life - Brief Clinical Inventory

    Time frame: At inclusion and 6 and 12 months following first initiation of automated mode

    Assess patients' diabetes-specific QoL

  20. Patients aged 10-17 years: Diabetes Quality of Life for Youth scale - Short Form (DQOLY-SF)

    Time frame: At inclusion and 6 and 12 months following first initiation of automated mode

    Assess patients' diabetes-specific QoL

  21. Insulin Delivery System Rating Questionnaire (IDSRQ) interference sub-score

    Time frame: At inclusion and 6 and 12 months following first initiation of automated mode

    Assess the interference of the Omnipod 5 System with patients' daily lives

  22. Patients aged ≥ 18 years: Diabetes Treatment Satisfaction Questionnaire, status version (DTSQs)

    Time frame: At inclusion and 6 and 12 months following first initiation of automated mode

    Assess patients' satisfaction with the Omnipod 5 System

  23. Patients aged 13-17 years: Diabetes Treatment Satisfaction Questionnaire, status version - Teens (DTSQs - Teen)

    Time frame: At inclusion and 6 and 12 months following first initiation of automated mode

    Assess patients' satisfaction with the Omnipod 5 System

  24. Patients aged 2-12 years: Diabetes Treatment Satisfaction Questionnaire, status version - Parent (DTSQs - Parent)

    Time frame: At inclusion and 6 and 12 months following first initiation of automated mode

    Assess patients' satisfaction with the Omnipod 5 System

  25. Pediatric quality of life questionnaire (animated emoji scale - ad hoc)

    Time frame: At inclusion and 6 and 12 months following first initiation of automated mode

    Assess pediatric patients' quality of life with the Omnipod 5 System

  26. Percentage of time using the System in automated mode

    Time frame: 12 months following first initiation of automated mode

    Describe System use

  27. Percentage of time using the System in manual mode

    Time frame: 12 months following first initiation of automated mode

    Describe System use

  28. Percentage of time using "Activity" feature

    Time frame: 12 months following first initiation of automated mode

    Describe System use

  29. Total daily dose of insulin

    Time frame: 12 months following first initiation of automated mode

    Describe System use

  30. Number of boluses per day

    Time frame: 12 months following first initiation of automated mode

    Describe System use

  31. Targets used by patients

    Time frame: 12 months following first initiation of automated mode

    Describe System use

  32. Bolus/Basal distribution

    Time frame: 12 months following first initiation of automated mode

    Describe System use

  33. Incidence of severe hypoglycemia

    Time frame: 6 months prior to switching to Omnipod 5 and over the 12 months following first initiation of automated mode

    Assess the incidence and type of acute metabolic complications

  34. Incidence of diabetic ketoacidosis

    Time frame: 6 months prior to switching to Omnipod 5 and over the 12 months following first initiation of automated mode

    Assess the incidence and type of acute metabolic complications

  35. Unscheduled hospitalizations for diabetes or diabetes complications.

    Time frame: 6 months prior to switching to Omnipod 5 and over the 12 months following first initiation of automated mode

    Assess the incidence and type of acute metabolic complications

  36. Percentage of patients still using the Omnipod 5 System at the end of study follow-up.

    Time frame: 12 months following first initiation of automated mode

    Assess the rate at which patients stop using the Omnipod 5 system

  37. Reasons for having stopped using the Omnipod 5 System

    Time frame: 12 months following first initiation of automated mode

    Assess the rate at which patients stop using the Omnipod 5 system

Sponsors and collaborators

Lead sponsor

Insulet Corporation

Industry

Registry information

Official study title

Omnipod 5 - A French Prospective Multicentric Study in Real World

Acronym: OPTIMAL-A

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jun 26, 2025
Registry last updated
Jul 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.